骨肉瘤驱动基因与免疫微环境及靶向治疗的研究进展
刘净峰
徐鸿锋
刘巍峰
100035 北京,首都医科大学附属北京积水潭医院骨肿瘤科
摘要：The 5-year survival rate of osteosarcoma(OS),the most common malignant bone tumor,has remained unchanged at 60%-70%for nearly 40 years.Its treatment mainly relies on surgical resection combined with multi-drug chemotherapy,but it is ineffective for patients with metastasis.In recent years,a series of clinical trials conducted around the world have not effectively improved the 5-year survival rate.However,along with the development of gene sequencing technology and related biomedicines,and the progress of precision medicine,a lot of progress has been made in the research of osteosarcoma driver genes,immune microenvironment,and targeted therapy.In this review,the research progress of osteosarcoma in terms of driver genes,immune microenvironment,and targeted therapy is expounded.
关键词：骨肉瘤分子靶向治疗细胞微环境驱动基因综述
分类号：R738.1(运动系肿瘤)
资助基金：国家重点研发计划(2023YFB4706300)国家重点研发计划(2021YFC2400500)北京市自然科学基金(L212042)北京市属医院科研培育计划项目(PX2021015)北京积水潭医院学科骨干计划(XKGG202105)北京积水潭医院院级科研基金(2023OSR-GCZX202206)
论文发表日期：2024-05-19
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 390-395 )
英文信息